LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group which was developed by Ligand Pharmaceuticals along with selective androgen receptor modulators (SARMs) like LG-121071 and was never marketed. The drug is a high-affinity antagonist of the androgen receptor (AR) with a Ki of 26 nM and has been found to inhibit growth of the ventral prostate and seminal vesicles in male rats interestingly without increasing circulating levels of luteinizing hormone or testosterone. However, this tissue selectivity has not been assessed in humans. LG-120907 is orally bioavailable and shows greater orally bioavailable potency than the arylpropionamide NSAA flutamide. References:

纯度：≥98%

CAS：201654-12-8